Glimepiride Improves Glycemic Control without Weight Gain in Japanese Obese Type 2 Diabetic Patients
スポンサーリンク
概要
- 論文の詳細を見る
Glimepiride was previously reported to not cause weight gain while improving glycemic control in Caucasian Type 2 diabetic patients.This prospective observational study evaluated the effect on weight, together with the efficacy and safety of glimepiride monotherapy for 6 months in Japanese obese Type 2 diabetic patients. Subjects were 394 Japanese obese (BMI ≥25 kg/m<SUP>2</SUP>, Japanese definition of obesity) Type 2 diabetic patients (mean age: 59.8±11.4 years), recruited from 70 study sites across Japan.Of these, 32%were oral hypoglycemic agent (OHA) naive 62%had switched from previous mono-or combination therapy with other hypoglycemic agents or insulin.The average dosage of glimepiride was 1.00 (median) and 1.71 (mean) mg/day.HbA<SUB>1</SUB>c improved significantly in 101 OHA naive patients [median:(25%, 75%), 7.30:(6.95, 7.70)% to 6.50:(5.95, 7.00)%, p=0.0000].A trend for improved HbA<SUB>1</SUB>c control was also observed in patients switching from other OHA monotherapy, while glycemic control was essentially maintained when switching from other SU agents.Glimepiride did not result in any clinical weight gain: In OHA naive patients, the median change in weight was only 1.0:(-0.5, 2.5) kg [69.6:(64.4, 79.5) kg to 71.0:(65.0, 79.7) kg].With 64% of patients completing the study in January-March, weight results were biased by the traditionally higher calorie intake during Japanese New Years holidays.In OHA naive patients in whom fasting immunoreactive insulin (F-IRI) and fasting plasma glucose (FPG) were measured, no significant change was observed in HOMA-IR [2.86:(1.78, 5.18) to 2.78:(1.93, 4.25), N.S.].Adverse effects, including hypoglycemia (2.07%), were observed in 4.40% of patients but none was serious.This study confirms that in relatively obese Japanese Type 2 diabetic patients, glimepiride provides satisfactory glycemic control and good safety, especially in OHA naive patients and patients switching from previous OHA monotherapy. Weight gain, although statistically significant, is considered to be clinically not relevant and likely to be influenced by seasonality rather than by glimepiride.The study confirms previous findings in Caucasians.
- 一般社団法人 日本糖尿病学会の論文
一般社団法人 日本糖尿病学会 | 論文
- Hyperlipidemia and Analysis of the Use of Lipid-lowering Drugs in Non-insulin-dependent Diabetes Mellitus.
- Thyrotoxic Crisis in a Patient with Mitochondrial Diabetes Mellitus.
- Rapidly Progressive Nephropathy in a Young Patient with Mitochondrial Gene Mutation.
- An Autopsy Case of Ketoacidosis in Insulin Dependent Diabetes Mellitus Patient Complicated with Adult Respiratory Distress Syndrome, DIC and Leukopenia.
- Studies on Alcoholic Beverages in Relation to Body Weight for Mild Diabetics